Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Quest Diagnostics

Related DGX
Earnings Scheduled For October 22, 2015
Quest Diagnostics' ExamOne Life Insurance Testing Business to Acquire Superior Mobile Medics

In a report published Monday, Jefferies & Company reiterated its Hold rating on Quest Diagnostics (NYSE: DGX), but lowered its price target from $63.00 to $59.00.

Jefferies noted, “We continue to have a neutral view on DGX given our belief that ongoing weakness in lab volumes will persist and keep the stock rangebound near-term. While we are optimistic that mgmt's efforts to restructure operations and rationalize expenses will achieve their targets, we recognize that this process, which could be the key catalyst for the stock, will take time to complete.”

Quest Diagnostics closed on Friday at $57.94.

Latest Ratings for DGX

Oct 2015BarclaysMaintainsEqualweight
Aug 2015Canaccord GenuityMaintainsBuy
Jun 2015Goldman SachsDowngradesBuyNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (DGX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters